Tumors remain one of the deadliest diseases in the world, accounting for around one in six deaths globally in 2020. While scientists may not have found a cure for life-threatening tumors despite decades of research, there are a variety of treatments that can reduce and even eliminate tumors. However, people who live in rural areas have limited access to cancer treatments that could save their lives, highlighting a startling inequality in access to lifesaving cancer treatments.
For starters, some cancer patients have had their tumors completely eradicated after undergoing Chimeric antigen receptor T-cell (CAR T-cell) therapy. However, patients who reside far away from major cities where most transplant centers are located have limited access to this and other critical treatments. CAR T-cell therapy is only offered in large transplant hospitals. This means that patients who could benefit from this therapy but don’t live in or close to major cities either have to migrate or miss out on the treatment.
For example, Suzanne BeHanna had been forced to migrate 750 miles from her home in rural New Mexico to receive treatment for lymphoma at the Houston-based University of Texas MD Anderson Cancer Center. By fall 2019, BeHanna was living in a trailer park in Houston and sick from two unsuccessful rounds of chemotherapy. The 62-year-old could have benefited from Car T-cell therapy if it was offered closer to her home, but at that point, she just wanted to go back home and spend her final days with her husband.
This revolutionary treatment involves extracting a patient’s T cells and genetically modifying them to add the chimeric antigen to essentially weaponize them against cancer cells before being infused back into the patient.
At the moment, only three companies are approved by the Food and Drug Administration (FDA) to make CAR-T cells: Norvatis, Myers Squibb and Gilead Sciences. In addition, the treatment is only available in some 150 transplant centers across the country. Since the side effects of CAR T-cell treatment can be fatal, patients that are cleared for this treatment have to be close to one of the 150 transplant centers in the country so specialists can keep a close eye on them.
Roughly one-half of U.S. adults live at least a half hour from a transplant center, leading to severely limited access to treatment for cancer patients in rural areas that are far from such treatment centers. The search for better cancer treatments is an ongoing one, with companies such as CNS Pharmaceuticals Inc. (NASDAQ: CNSP) focused on developing superior treatments targeting oncology conditions affecting the brain.
NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
BioMedWire is part of the InvestorBrandNetwork.